(1R,2R,3S,4R)-2,3,4-triacetoxy-1-(acetoxymethyl)cyclopentane | 118013-62-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,2R,3S,4R)-2,3,4-triacetoxy-1-(acetoxymethyl)cyclopentane
• 英文别名: 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose；[(1R,2R,3S,4R)-2,3,4-triacetyloxycyclopentyl]methyl acetate
• CAS: 118013-62-0
• 化学式: C₁₄H₂₀O₈
• 分子量: 316.308
• InChiKey: MSZKNSYGZGPKPT-SYQHCUMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (1R,2R,3S,4R)-2,3,4-triacetoxy-1-(acetoxymethyl)cyclopentane 生成 (1R,2S,3R,4R)-4-(hydroxymethyl)cyclopentane-1,2,3-triol
  参考文献：
  名称：

  TADANO, KIN-ICHI;HAKUBA, KEN;KIMURA, HIROSHI;OGAWA, SEIICHIRO, J. ORG. CHEM., 54,(1989) N, C. 276-279

  摘要：

  DOI：
• 作为产物：
  描述：

  (1R,2S)-2-Benzyloxy-4-hydroxymethyl-cyclopentane-1,3-diol 在 palladium on activated charcoal 吡啶 、 氢气 、 sodium methylate 作用下， 以 甲醇 、 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 30.0h， 生成 (1R,2R,3S,4R)-2,3,4-triacetoxy-1-(acetoxymethyl)cyclopentane
  参考文献：
  名称：

  Syntheses of (1S,2S,3S,4R)- and (1R,2R,3S,4R)-2,3,4-trihydroxycyclopentane-1-methanol, carbocyclic analogs of .alpha.-L-arabinofuranose and .beta.-D-ribofuranose

  摘要：

  DOI：

  10.1021/jo00263a005

文献信息

• USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS
  申请人：Pizzorno Giuseppe

  公开号：US20080182806A1

  公开（公告）日：2008-07-31

  Compositions and methods for treating various diseases and disorders, such as for a myeldoysplastic syndrome are provided. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one of an esterificated azacytidine, an acetylated azacitidine, an esterificated decitabine, and an acetylated decitabine, such as 2′,3′,5′-triacetyl-5-azacytidine.

  本发明提供了用于治疗各种疾病和障碍的组合物和方法，例如用于治疗骨髓增生异常综合症。该方法包括向受试者施用治疗有效量的制药组合物，该制药组合物包括至少一种酯化的氮杂胞苷、乙酰化的氮杂胞苷、酯化的脱氧胞苷和乙酰化的脱氧胞苷，例如2′，3′，5′-三乙酰基-5-氮杂胞苷。
• Modulators of 5′-nucleotidase, ecto and the use thereof
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US11001603B2

  公开（公告）日：2021-05-11

  Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

  本文描述了调节 5′-核苷酸酶将 AMP 转化为腺苷的化合物，以及含有这些化合物的组合物和合成这些化合物的方法。还提供了这些化合物和组合物用于治疗和/或预防由 5′-核苷酸酶外切酶介导的各种疾病、失调和病症，包括癌症和免疫相关失调。
• MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US20210002322A1

  公开（公告）日：2021-01-07

  Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.
• CD73 INHIBITORS AND USES THEREOF
  申请人：Peloton Therapeutics, Inc.

  公开号：US20210317150A1

  公开（公告）日：2021-10-14

  Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.